Reuters: Regulatory News: India's Sun Pharma gets FDA approval for diabetes generic drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

India's Sun Pharma gets FDA approval for diabetes generic drug Jul 12th 2013, 02:58 July 12 | Thu Jul 11, 2013 10:58pm EDT July 12 (Reuters) - India's Sun Pharmaceutical Industries said on Friday it has received final approval from the United States Food and Drug Administration (FDA) to launch the generic version of Novo Nordisk's Prandin diabetes drug. Prandin, known chemically as repaglinide, and its combination with the commonly prescribed type 2 diabetes drug metformin, sold as PrandiMet, had sales of about $200 million in 2012 for Novo. Sun Pharma said it would be eligible for a 180-day marketing exclusivity in the United States for the drug. A U.S. appeals court last month found the patent on Novo's Prandin diabetes drug in combination with metformin to be invalid, paving the way for the introduction of a generic version of the drug.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions